Bristol-Myers Squibb Company (BMY): Today's Featured Health Care Winner

Bristol-Myers Squibb Company ( BMY) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.3%. By the end of trading, Bristol-Myers Squibb Company rose $0.57 (1.3%) to $44.54 on light volume. Throughout the day, 6,068,417 shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10,876,100 shares. The stock ranged in a price between $44.14-$44.68 after having opened the day at $44.28 as compared to the previous trading day's close of $43.97. Other companies within the Health Care sector that increased today were: Inovio Pharmaceuticals ( INO), up 24.2%, CytRx Corporation ( CYTR), up 20.9%, Prosensa ( RNA), up 19.6% and Redhill Biopharma ( RDHL), up 18.3%.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $72.6 billion and is part of the drugs industry. Shares are up 34.9% year to date as of the close of trading on Monday. Currently there are 7 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 11 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Biota Pharmaceuticals ( BOTA), down 70.1%, Pingtan Marine Enterprise ( PME), down 65.1%, Mast Therapeutics ( MSTX), down 38.6% and Oramed Pharmaceuticals ( ORMP), down 13.9% , were all laggards within the health care sector with Intuitive Surgical ( ISRG) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Bristol-Myers Squibb Stock Still a Beast?

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Achillion Shares Are Plunging on Termination of Hepatitis C Pact